About 69,100 results
Open links in new tab
  1. 340B Drug Pricing Program | HRSA

    The 340B Program enables covered entities to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services. …

  2. 340B Eligibility | HRSA

    Discover eligibility and registration details for HRSA's 340B Drug Pricing Program to help entities access discounted medications

  3. 340B Educational Resources | HRSA

    Our website provides resources to help 340B Program stakeholders with navigating the 340B Program, including registration and implementation, requirements compliance, program …

  4. Program Requirements | HRSA

    To purchase drugs at the 340B price, covered entities must continue to meet the requirements of the 340B Drug Pricing Program.

  5. 340B Rebate Model Pilot Program | HRSA

    The 340B rebate model pilot is applicable to all selected drugs under IPAY 2026 to the extent they are covered outpatient drugs, including physician- or clinic-administered drugs.

  6. FAQs | HRSA

    Which manufacturers and drugs are subject to 340B pricing, and can participating manufacturers offer only a subset of the drugs they manufacture at 340B prices?

  7. 340B Office of Pharmacy Affairs Information System | HRSA

    The 340B registration and pricing databases are known as the 340B Office of Pharmacy Affairs Information System (340B OPAIS). Authorized users of 340B OPAIS must have a user …

  8. 340B-Search Covered Entities

    Search for covered entities participating in the 340B Drug Pricing Program using this tool provided by HRSA.

  9. Ceiling Price Lookup

    In order to calculate the 340B ceiling price, the Unit Rebate Amount (URA) is subtracted from the Average Manufacturer Price (AMP) for the smallest unit of measure [340B Ceiling Price = …

  10. Contract Pharmacy Services | HRSA

    A contract pharmacy must register for the 340B Program and ensure compliance with all 340B Program requirements before giving out 340B drugs for a covered entity.